Applying a Multidisciplinary Intervention for Drug Adequacy in an Intermediate Care Hospital (AMIDA-ICH)

NCT ID: NCT07015112

Last Updated: 2025-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-04

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if a multi-professional (conducted by geriatricians, clinical pharmacists, nurses) medication revision, centered on patients' goals and characteristics, can improve treatment adequacy in older adults admitted to an intermediate care hospital.

The main question it aims to answer is: does this approach reduce the average number of medications taken per patient?

Researchers will compare this multi-professional patient-centered revision to the usual standard of care (treatment revision conducted by a clinical pharmacist) to see if the patient-centered revision works in improving treatment adequacy.

Participants admitted to an intermediate care hospital will undergo a comprehensive assessment by a geriatrician, and a medication revision (conducted by a multidisciplinary team or a clinical-pharmacist alone). They will also be asked to fulfill some questionnaires on their health status and attitudes. Any possible adverse events to the medications will be recorded at discharge. Participants will be contacted again three months after discharge to check for any readmission or death.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Poly Pharmacy Frail Elderly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Stepped-wedge
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control (usual care)

Control arm will receive usual standard of care

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention (patient-centered medication review)

Intervention arm will receive a multidisciplinary patient-centered medication review

Group Type EXPERIMENTAL

Patient-centered multidisciplinary treatment review

Intervention Type OTHER

Patient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient-centered multidisciplinary treatment review

Patient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* older adults (65+ years)
* ≥ 3 or more chronic conditions requiring medical therapy
* able to speak Spanish
* capacity to provide informed consent or have a surrogate able to consent on their behalf

Exclusion Criteria

* unable to provide informed consent
* anticipated length of hospital stay \< 72h
* estimated life expectancy \< 3 months
* homeless
* already enrolled in a drug trial
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Parc Sanitari Pere Virgili

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Parc Sanitari Pere Virgili

Barcelona, Barcelona, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ana M de Andrés Lázaro, Pharmacist. PhD

Role: CONTACT

+34932594128

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ana M de Andrés Lázaro, Pharmacist, PhD

Role: primary

+34 93 259 41 28

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AMIDA-ICH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Decreasing Polypharmacy in Older Adults With Curable Cancers Trial
NCT05046171 ACTIVE_NOT_RECRUITING PHASE1/PHASE2